HC Wainwright Has Negative Estimate for TLX FY2025 Earnings

Telix Pharmaceuticals Limited (NASDAQ:TLX) – HC Wainwright decreased their FY2025 earnings estimates for Telix Pharmaceuticals in a report issued on Monday, December 22nd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.19 for the year, down from their prior forecast of $0.28. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. HC Wainwright also issued estimates for Telix Pharmaceuticals’ FY2026 earnings at $0.59 EPS.

A number of other equities analysts also recently weighed in on TLX. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. UBS Group dropped their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Citigroup initiated coverage on Telix Pharmaceuticals in a research report on Thursday, September 18th. They issued a “buy” rating and a $22.00 price objective on the stock. Royal Bank Of Canada began coverage on Telix Pharmaceuticals in a research report on Monday, December 15th. They set a “hold” rating for the company. Finally, Wall Street Zen cut Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Up 0.5%

Shares of TLX stock opened at $8.09 on Wednesday. Telix Pharmaceuticals has a 52-week low of $7.72 and a 52-week high of $30.36. The company has a 50-day simple moving average of $9.72 and a two-hundred day simple moving average of $11.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TLX. Rhumbline Advisers raised its stake in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the period. IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals in the second quarter valued at approximately $213,000. Blair William & Co. IL purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at approximately $217,000. JPMorgan Chase & Co. bought a new position in Telix Pharmaceuticals in the 3rd quarter worth approximately $243,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Telix Pharmaceuticals during the second quarter worth $297,000.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with a $20 price target, a bullish analyst view that signals upside potential if Telix can resolve regulatory/legal issues and re‑accelerate product progress. Benzinga
• Negative Sentiment: Multiple plaintiff and shareholder‑rights law firms are urging Telix investors to act by Jan. 9, 2026 in a newly filed securities class action covering Feb 21–Aug 28, 2025 — publicity increases litigation risk, potential damages exposure, and ongoing legal costs. Representative notices: Levi & Korsinsky. Levi & Korsinsky, The Law Offices of Frank R. Cruz. Frank R. Cruz
• Negative Sentiment: Additional firms are circulating similar notices (Hagens Berman, Berger Montague, Gross Law, Faruqi & Faruqi, Portnoy, Bronstein)—the volume of notices amplifies investor attention and could pressure sentiment until regulatory and legal clarity arrives. Representative notices: Hagens Berman (calls out SEC subpoena & FDA CRL tied to CMC/supply chain), Berger Montague. Hagens Berman 21% plunge / SEC subpoena & FDA CRL Berger Montague

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.